Esophagus News

The biomarker-based Esopredict determined that patients with Barrett’s esophagus who were stratified as higher risk were 6.4-times more likely to progress to high-grade dysplasia or esophageal adenocarcinoma within 5 years, research showed.

“Aggressive” combination therapy for gastroesophageal reflux disease improved survival among patients with systemic sclerosis and interstitial lung disease, according to data published in Arthritis Research & Therapy.

Researchers found associations between Index of Severity for Eosinophilic Esophagitis scores and select clinical features across categories of disease severity, according to a study published in The Journal of Allergy and Clinical Immunology.

Treatment with Dupixent led to histologic remission at week 16 among a greater percentage of pediatric patients with eosinophilic esophagitis refractory to proton-pump inhibitor therapy compared with placebo, according to study results.

The FDA has expanded approval for Phathom Pharmaceuticals’ Voquezna tablets 10 mg to alleviate heartburn related in non-erosive gastroesophageal reflux disease, according to a company press release.

Targeted screening of older adults with GERD and a 5% probability of Barrett’s esophagus or esophageal adenocarcinoma could “substantially decrease” the population to screen, while still detecting more than 70% of disease, data showed.

There were significant differences in percentages of children with eosinophilic esophagitis who experienced histologic remission with dupilumab compared with placebo, according to a study published in The New England Journal of Medicine.

Fewer ventilated patients who received pantoprazole, a widely available proton-pump inhibitor, experienced clinically important upper gastrointestinal bleeding, according to research published in the New England Journal of Medicine.

In a new clinical practice guideline, the AGA provides evidence-based recommendations for use of endoscopic eradication therapy in the management of Barrett’s esophagus, accounting for the presence of dysplasia and other scenarios.